Simard John's Form 4 filing
XBiotech Inc.XBIT · filed Feb 15, 2022
- Accession no.
- 0001209191-22-009745
- Filed
- Feb 15, 2022
- Trade date
- Oct 15-18, 2021
- Filing delay
- 123 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market sales total $657.8K. It was filed 123 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Simard JohnCIK 0001639078 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions. The reporting person undertakes to provide to XBIT, any security holder of XBIT, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Referenced by the price of 2 transactions in Table I.
Remarks
John Simard, CEO Chairman of XBiotech, Inc., adopted a stock trading plan. He sold total of 50,000 common stock on the open market as part of this 10B5-1 trading plan.